Vertex VX-880: The "Functional Cure" for Type 1 Diabetes Shows Durable Results

Clinical Trials · 4 · March 21, 2026

!Vertex Stem Cell Lab

For Type 1 diabetics, the immune system destroys the pancreas's ability to make insulin. The "Holy Grail" of research has been to replace those lost cells. Vertex Pharmaceuticals is doing just that with VX-880, and the latest Phase 1/2 data is nothing short of revolutionary.

The "Functional Cure"

In the ongoing study, patients with severe Type 1 diabetes—those with "hypoglycemic unawareness" (dangerous drops in blood sugar they can't feel)—received an infusion of stem cell-derived islet cells.

The results reported in late 2025 were stunning:

• Insulin Production: All treated patients showed restored insulin production (C-peptide levels).
• Freedom from Injections: Several patients achieved total insulin independence. They no longer need pumps or shots.
• Safety: No serious adverse events related to the cells were reported.

The Catch: Immunosuppression

Currently, VX-880 requires patients to take immunosuppressive drugs to prevent their body from attacking the new cells. This is a trade-off: trading insulin for immune-suppressing pills.

However, Vertex is already working on VX-264, a "cloaked" version of the therapy where cells are encapsulated in a device that protects them from the immune system, potentially eliminating the need for drugs.

Why This Matters Now

This isn't just a lab experiment; it's a commercial track therapy. Vertex is moving aggressively toward pivotal trials. For patients, this means a tangible hope that Type 1 diabetes could become a manageable condition—or even a memory—within this decade.